For reasons such as water quality to taste, an increasing number of people are choosing bottled water over tap water. But while consumers seem to recognize the benefits of drinking bottled water, few of them realize that there are huge differences in quality among different brands. One of the best and most successful bottled water companies has been Waiakea Water, which bottles water that has been filtered through porous volcanic rock from Hawaii’s Mauna Loa volcano.
As fresh water from the constant rainfall around Mauna Loa passes through volcanic rock, it picks up minerals such as calcium and magnesium. These minerals have numerous health benefits, and they also give Waiakea Water a naturally alkaline pH of 8.2, whereas other bottled water brands range from 4 to 7 pH. Because Waiakea Water’s pH is kept above a neutral 7, it is never acidic; this is another health benefit because consuming acidic foods and beverages can be hazardous to your health. Bottling water that has been filtered through volcanic rock also ensures that Waiakea is naturally sourced, which limits the company’s environmental impact. Combined with Waiakea water’s superior quality, this has made the brand a popular choice among consumers.
Waiakea was founded in 2012 by CEO Ryan Emmons. After Emmons realized that the water his family drank at their home in Hawaii was of such a high quality, he decided to bottle it to provide consumers with naturally superior water. Waiakea is the first Hawaiian bottled water of its kind, and is also the first bottled water company to utilize the ‘triple bottom line’ model, which prioritizes social and environmental impact along with financial gain.
In line with the triple bottom line philosophy, Waiakea gives back to underprivileged communities by donating a weeks’ worth of clean water to people in need for each liter they sell. Waiakea partners with Pump Aid for this endeavor, and providing clean water to as many people as possible has rapidly become part of Waiakea’s mission statement.
Waiakea has also been presented with several awards in recognition of their success. They have received the National Restaurant Association’s Food and Beverage Innovation Award as well as a World Beverage Innovation award, and they were also named one of the top 10 “Most innovative food companies out there” by Good Morning America. Waiakea Water has also been featured in Forbes, People, Beverage World and Organic Authority.
Sleep apnea can affect anyone and for several different reasons. Factors could be your hectic lifestyle or old age. Sleep apnea can disrupt your everyday life and lead to serious health consequences. Dr. Avi Weisfogel is a highly reputable doctor who has identified ways to prevent and treat sleep apnea. During his research, he found several different causes of sleep apnea and lack of sleep. He developed programs and therapies that can help patients combat the infection. While researching other diseases, he found that there was a connection between diabetes, stroke and sleep apnea.
Dr. Avi Weisfogel is the specialist who created Dental Sleep Masters
. This is a program that helps dentists prescribe solutions to their patients that work. Many people may not have realized that dentists can provide great insight on sleep disorders. The program is marketed towards dentists giving them cutting-edge technology to help treat their patients. Dr. Weisfogel has conducted many lectures on the subject of sleep disorders. So many are ill-informed when it comes to the topic of sleep apnea and sleep disorders. The technology he uses has enabled dentists to accurately diagnose sleep apnea in their patients. Dr. Avi Weisfogel has unsurpassed experience
and education in the industry. He graduated from the New York University College of Dentistry
and has a degree in Psychology from Rutgers University. He started his first dental practice
, Old Bridge Dental Care in 1999. During the first 15 years of his career
, Dr. Weisfogel was named Best Dentist by his community.
Nurturing and caring for the children of tomorrow is a responsibility that everyone shares; nurturing their minds, and bodies so they themselves can push the boundaries of our world. This is just one of the many beliefs of Amicus Therapeutics.
Amicus Therapeutics is global biotechnology company that leads in the innovation of treating rare and orphan diseases. These mainly include diseases that deal lysosomal storage disorders such as Fabry disease and Pompe disease. Epidermolysis Bullosa (EB) is another disease that Amicus Therapeutics is thoroughly invested in. Being at the forefront of treatments for these diseases is the mission Amicus Therapeutics is trying to achieve. Under the leadership of John F. Crowley, who is the Chairman and CEO, Amicus Therapeutics is taking amazing strides towards treatments that could revolutionize the biotech industry. Mr. Crowley has two children of his own who was diagnosed with Pompe disease. This led him on a journey to not only find a treatment for his own children but to give the children of tomorrow a fighting chance against such diseases.
Amicus Therapeutics is currently most known for their drug Migalastat or Galafold. This drug is a long-term treatment option for children who suffer from Fabry disease. But even with this amazing achievement Amicus Therapeutics is still working towards helping children with other diseases as well. They currently have a Proprietary Topical Formulation (SD-101) that is in its phase three of its clinical trials for the disease Epidermolysis Bullosa, as well as a Novel Enzyme Replacement Therapy, Novel ERT for short, for Pompe Disease (ATB200/AT2221).
Not only does Amicus Therapeutics continue their works through their own organization and treatments but through other non-profit organizations as well. Amicus Therapeutics believes in spreading awareness of these diseases as well as providing services, and activities for those in need. From their actions, Amicus Therapeutics have proved that they are committed to improving every aspect of life.
More about Amicus Therapeutics at https://finance.yahoo.com/quote/FOLD?ltr=1